Analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of Merck & Co., Inc. in a research report issued to clients and investors on Friday, January 24th. Leerink Partnrs analyst D.

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...

Intuitive Surgical (NASDAQ:ISRG – Free Report) had its target price boosted by JPMorgan Chase & Co. from $575.00 to $675.00 ...

TNYA Stock Performance and Moving Averages. In recent trading, Tenaya Therapeutics Inc (TNYA) stock price has shown some volatility, fluctuating -12.95% over the last five trades ...

Walgreens Boots Alliance Inc (WBA) stock saw a modest uptick, ending the day at $11.87 which represents a slight increase of $0.13 or 1.11% from the prior close of $11.74. The stock opened at $11.65 ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

For IDRx, Centerview Partners LLC is acting as exclusive financial advisor and Goodwin Procter LLP as legal counsel. For GSK, Leerink Partners LLC is acting as the exclusive financial advisor. IDRX-42 ...

For IDRx, Centerview Partners LLC is acting as exclusive financial advisor and Goodwin Procter LLP as legal counsel. For GSK, Leerink Partners LLC is acting as the exclusive financial advisor.